Trump's Generic Drug Manufacturing Push Faces Steep Obstacles
Reviving U.S. generic drug production is a stated White House goal, but cost and supply-chain realities make it extraordinarily difficult.
President Trump has made reshoring pharmaceutical manufacturing a policy priority, but the global generic drug industry illustrates why that ambition is far easier to declare than to execute. Countries like India have spent decades building cost structures and supply networks that American factories would struggle to match in the near term.
Generic drugs, which account for the vast majority of prescriptions filled in the United States, are produced overwhelmingly abroad because labor costs and established supply chains give foreign manufacturers a decisive price advantage. Replicating those conditions domestically would require significant capital investment and time — two resources that market incentives do not currently favor.
Read more Cuban Exiles in Florida Eye Havana as Regime Change Hopes Grow →
India, in particular, has emerged as a dominant global supplier of generic pharmaceuticals, underpinned by low wages, a mature chemical-ingredient industry, and decades of regulatory experience with U.S. and European markets. American manufacturers would face that entrenched competition even if tariffs or subsidies were introduced to level the playing field.
Policy analysts note that bringing generic drug production home is not simply a matter of political will. Factory construction, workforce training, and raw-material sourcing all take years to scale, meaning any meaningful domestic capacity increase would be a long-range project rather than a near-term solution to supply-chain vulnerabilities exposed during the pandemic.
The structural gap between ambition and economic reality underscores the complexity facing U.S. trade and health policy as the administration seeks to reduce dependence on foreign pharmaceutical sources. Continue reading at NYT > Business.
